M Trum, J Riechel, E Schollmeier, S Lebek, P Hegner, K Reuthner, S Heers, K Keller, M Wester, S Klatt, N Hamdani, Z Provaznik, C Schmid, L S Maier, M Arzt, S Wagner
AIMS: Heart failure with preserved ejection fraction (HFpEF) causes substantial morbidity and mortality. Importantly, atrial remodeling and atrial fibrillation is frequently observed in HFpEF. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have recently been shown to improve clinical outcomes in HFpEF, and post-hoc analyses suggest atrial antiarrhythmic effects. We tested if isolated human atrial cardiomyocytes from patients with HFpEF exhibit an increased Na influx, which is known to cause atrial arrhythmias, and if that is responsive to treatment with the SGTL2i empagliflozin...
May 10, 2024: Cardiovascular Research